Version 1
: Received: 29 June 2023 / Approved: 30 June 2023 / Online: 30 June 2023 (14:11:59 CEST)
How to cite:
Kashfi, K.; Anbardar, N.; Asadipooya, A.; Asadipooya, K. Type1 Diabetes and COVID-19: A Systematic Review and Possible Management. Preprints2023, 2023062265. https://doi.org/10.20944/preprints202306.2265.v1
Kashfi, K.; Anbardar, N.; Asadipooya, A.; Asadipooya, K. Type1 Diabetes and COVID-19: A Systematic Review and Possible Management. Preprints 2023, 2023062265. https://doi.org/10.20944/preprints202306.2265.v1
Kashfi, K.; Anbardar, N.; Asadipooya, A.; Asadipooya, K. Type1 Diabetes and COVID-19: A Systematic Review and Possible Management. Preprints2023, 2023062265. https://doi.org/10.20944/preprints202306.2265.v1
APA Style
Kashfi, K., Anbardar, N., Asadipooya, A., & Asadipooya, K. (2023). Type1 Diabetes and COVID-19: A Systematic Review and Possible Management. Preprints. https://doi.org/10.20944/preprints202306.2265.v1
Chicago/Turabian Style
Kashfi, K., Artin Asadipooya and Kamyar Asadipooya. 2023 "Type1 Diabetes and COVID-19: A Systematic Review and Possible Management" Preprints. https://doi.org/10.20944/preprints202306.2265.v1
Abstract
Introduction SARS-CoV-2 infection normally damages respiratory system but may likewise impair endocrine organs’ function. Thyroid dysfunction and hyperglycemia are common endocrine complications of SARS-CoV-2 infection. Onset of T1D and associated complications including DKA, hospitalization and death, are thought to be increased during the COVID-19 pandemic. The aim of this study is to review the available data about the incidence rate of T1D and accompanying complications since the beginning of the COVID-19 pandemic.
Methods: A systematic review was conducted using electronic databases PubMed and Google Scholar. The keywords “T1D, T1DM, Type 1 DM or Type 1 Diabetes”, “Coronavirus, SARS-CoV-2 or COVID-19” were used to search these databases. Titles and abstracts were screened for selection, and then relevant studies were reviewed in full text.
Result: we selected 21 manuscripts out of 296 identified studies. Data about the incidence rate of T1D, hospitalization and death are not consistent across countries, but DKA incidence and severity seem to be higher during the COVID-19 pandemic.
Conclusion: Our data collection demonstrated that COVID-19 may or may not increase the incidence of type 1 diabetes. Nevertheless, it is associated with higher incidence and severity of DKA in T1D patients. Antivirals are not fully protective against endocrine complications of SARS-CoV-2 infection. Combining medications that reduce SARS-CoV-2 entry into the cells and modulate the immune response to infection is an alternative practical approach to treating COVID-19.
Keywords
ACE2, DKA, SARS-CoV-2, T1D
Subject
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
